-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the medical industry has frequently gained capital overweight, and financing has been very active
.
According to incomplete statistics, in 2020, 30 medical digital enterprises in China will receive financing, with a total financing amount of about 11.
534 billion yuan
.
Since 2021, this financing boom has continued
.
Recently, Reindeer Medical announced the completion of US$108 million in Series C financing
.
According to the announcement, the financing was led by CDH Baifu, with CCB International as the main investor; China Everbright, Cornerstone Capital, CNCB Investment, and Plaisance Capital followed up the investment; existing shareholders Hillhouse Ventures continued to increase Cast
.
It is understood that this round of financing will be used to accelerate the pre-clinical research, clinical development, listing application and commercialization of various innovative cell therapies of Reindeer Medical
.
In addition, the company will use the funds raised to develop a broader allogeneic and solid tumor treatment cell product pipeline, expand global cooperation with core products, and further enrich the existing product pipeline
.
On September 16, Gaorong Technology, a minimally invasive interventional surgery robot company for tumors, announced that it has completed a Pre-A round of financing of tens of millions of yuan.
Xiaomiao Langcheng led the investment, and Bangming Capital and other co-investments.
The old shareholder Haimaide Ventures continued Overweight, Potential Capital serves as the exclusive financial advisor
.
This round of financing will accelerate the progress of Gaorong Technology in talent introduction, product development, clinical trials and marketing promotion, so that doctors and patients can complete minimally invasive tumor interventional surgery through robots earlier and benefit from its applications
.
On September 14, Qianglian Zhichuang (Beijing) Technology Co.
, Ltd.
(hereinafter referred to as "Qianglian Zhichuang" or "the company"), a domestic integrated solution provider for intelligent diagnosis and treatment of cerebrovascular diseases, also announced the completion of hundreds of millions of yuan.
Series C financing
.
According to the data, Qianglian Zhichuang is the first domestic AI solution company that focuses on stroke prevention and first aid diagnosis and treatment, and has a complete stroke product matrix.
.
At present, relying on many algorithms and technologies that remain at the forefront of the world, it is committed to allowing AI diagnosis and treatment services to sink to the grassroots, so that tens of millions of patients with cerebrovascular disease and nearly 100 million people at high risk of stroke in China can get more timely and peaceful treatment.
More effective treatment can increase the cure rate and reduce the rate of death and disability, while further reducing the overall medical expenditure
.
In fact, from the overall point of view, the medical industry has become a well-deserved "star industry" in recent years
.
The performance and enthusiasm of the financing market undoubtedly demonstrate the fiery development of the medical and health field
.
In this regard, industry analysts believe that the current development of China's medical industry is in a period of accelerated transformation.
The price reduction of centralized procurement of medicines and consumables will greatly reduce the medical burden of patients and the country, and further promote the inclusiveness and accessibility of medical care
.
In this context, medical companies continue to obtain financing, which will also inject more impetus into the pharmaceutical market, thereby further promoting the development of the entire industry
.
.
According to incomplete statistics, in 2020, 30 medical digital enterprises in China will receive financing, with a total financing amount of about 11.
534 billion yuan
.
Since 2021, this financing boom has continued
.
Recently, Reindeer Medical announced the completion of US$108 million in Series C financing
.
According to the announcement, the financing was led by CDH Baifu, with CCB International as the main investor; China Everbright, Cornerstone Capital, CNCB Investment, and Plaisance Capital followed up the investment; existing shareholders Hillhouse Ventures continued to increase Cast
.
It is understood that this round of financing will be used to accelerate the pre-clinical research, clinical development, listing application and commercialization of various innovative cell therapies of Reindeer Medical
.
In addition, the company will use the funds raised to develop a broader allogeneic and solid tumor treatment cell product pipeline, expand global cooperation with core products, and further enrich the existing product pipeline
.
On September 16, Gaorong Technology, a minimally invasive interventional surgery robot company for tumors, announced that it has completed a Pre-A round of financing of tens of millions of yuan.
Xiaomiao Langcheng led the investment, and Bangming Capital and other co-investments.
The old shareholder Haimaide Ventures continued Overweight, Potential Capital serves as the exclusive financial advisor
.
This round of financing will accelerate the progress of Gaorong Technology in talent introduction, product development, clinical trials and marketing promotion, so that doctors and patients can complete minimally invasive tumor interventional surgery through robots earlier and benefit from its applications
.
On September 14, Qianglian Zhichuang (Beijing) Technology Co.
, Ltd.
(hereinafter referred to as "Qianglian Zhichuang" or "the company"), a domestic integrated solution provider for intelligent diagnosis and treatment of cerebrovascular diseases, also announced the completion of hundreds of millions of yuan.
Series C financing
.
According to the data, Qianglian Zhichuang is the first domestic AI solution company that focuses on stroke prevention and first aid diagnosis and treatment, and has a complete stroke product matrix.
.
At present, relying on many algorithms and technologies that remain at the forefront of the world, it is committed to allowing AI diagnosis and treatment services to sink to the grassroots, so that tens of millions of patients with cerebrovascular disease and nearly 100 million people at high risk of stroke in China can get more timely and peaceful treatment.
More effective treatment can increase the cure rate and reduce the rate of death and disability, while further reducing the overall medical expenditure
.
In fact, from the overall point of view, the medical industry has become a well-deserved "star industry" in recent years
.
The performance and enthusiasm of the financing market undoubtedly demonstrate the fiery development of the medical and health field
.
In this regard, industry analysts believe that the current development of China's medical industry is in a period of accelerated transformation.
The price reduction of centralized procurement of medicines and consumables will greatly reduce the medical burden of patients and the country, and further promote the inclusiveness and accessibility of medical care
.
In this context, medical companies continue to obtain financing, which will also inject more impetus into the pharmaceutical market, thereby further promoting the development of the entire industry
.
